Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 4, 2026, 7:33 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 141 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Single-ventricle Clear all
Recruiting Phase 3 Interventional

A Study to Learn More About How Safe Finerenone is, When it is Taken for a Longer Time With Standard Treatment, in Children and Young Adults With Heart Failure and Left Ventricular Systolic Dysfunction

NCT07192952
View directory record Official record
Conditions
Left Ventricular Systolic Dysfunction, Heart Failure (Pediatric)
Interventions
Finerenone (Kerendia, BAY94-8862)
Drug
Lead sponsor
Bayer
Industry
Eligibility
Up to 18 Years
Enrollment
117 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
22
States / cities
Aurora, Colorado • Wilmington, Delaware • Gainesville, Florida + 18 more
Source: ClinicalTrials.gov public record
Updated Jun 28, 2026 · Synced Sep 4, 2026, 7:33 PM EDT
Completed Phase 3 Interventional Results available

Fontan Udenafil Exercise Longitudinal Assessment Trial

NCT02741115
View directory record Official record
Conditions
Single Ventricle Heart Disease
Interventions
Udenafil, Placebo
Drug
Lead sponsor
Mezzion Pharma Co. Ltd
Industry
Eligibility
12 Years to 18 Years
Enrollment
400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
26
States / cities
Phoenix, Arizona • Los Angeles, California • San Diego, California + 22 more
Source: ClinicalTrials.gov public record
Updated Jun 16, 2025 · Synced Sep 4, 2026, 7:33 PM EDT
Completed Phase 1 Interventional Results available

Single Ascending Doses of GGF2 in Patients With Left Ventricular Dysfunction and Symptomatic Heart Failure

NCT01258387
View directory record Official record
Conditions
Heart Failure
Interventions
Glial growth factor 2/ Neuregulin 1β3, Placebo
Drug · Other
Lead sponsor
Acorda Therapeutics
Industry
Eligibility
18 Years to 75 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
2
States / cities
Atlanta, Georgia • Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Jun 30, 2014 · Synced Sep 4, 2026, 7:33 PM EDT
Completed Not applicable Interventional

Re-Energize Fontan

NCT04195451
View directory record Official record
Conditions
Single-ventricle
Interventions
Live-Video-Supervised Exercise Intervention, Usual Care then Live-Video Supervised Exercise Intervention
Other
Lead sponsor
Stanford University
Other
Eligibility
8 Years to 19 Years
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
1
States / cities
Palo Alto, California
Source: ClinicalTrials.gov public record
Updated Jun 21, 2026 · Synced Sep 4, 2026, 7:33 PM EDT
Completed Phase 3 Interventional Results available

A Extension Study of Udenafil in Adolescents

NCT03013751
View directory record Official record
Conditions
Functional Single Ventricle Heart Disease
Interventions
Udenafil
Drug
Lead sponsor
Mezzion Pharma Co. Ltd
Industry
Eligibility
12 Years to 18 Years
Enrollment
301 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
21
States / cities
Phoenix, Arizona • Los Angeles, California • San Diego, California + 18 more
Source: ClinicalTrials.gov public record
Updated Dec 8, 2025 · Synced Sep 4, 2026, 7:33 PM EDT
Recruiting Not applicable Interventional

Ablation-Index Guided Scar-Mediated Ventricular Tachycardia Ablation in Patients With Ischemic Cardiomyopathy

NCT06138873
View directory record Official record
Conditions
Ventricular Tachycardia, Ischemic Cardiomyopathy
Interventions
Ablation-index guided ventricular tachycardia ablation, Ventricular tachycardia ablation with no AI-guidance
Procedure
Lead sponsor
Rush University Medical Center
Other
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
5
States / cities
Chicago, Illinois • Boston, Massachusetts • Ann Arbor, Michigan + 2 more
Source: ClinicalTrials.gov public record
Updated Sep 21, 2025 · Synced Sep 4, 2026, 7:33 PM EDT
Terminated Phase 2 Interventional Results available

Hemodynamic and Echocardiographic Assessment of Riociguat Effects on Myocardial Wall Contractility and Relaxation Kinetics

NCT01065051
View directory record Official record
Conditions
Hypertension, Pulmonary, Ventricular Dysfunction, Left
Interventions
Riociguat (Adempas, BAY63-2521), Placebo
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
2
States / cities
Boston, Massachusetts • Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Jan 5, 2014 · Synced Sep 4, 2026, 7:33 PM EDT
Recruiting Not applicable Interventional

Trial in Arrhythmia Radioablation for Ventricular Tachycardia: Single Fraction vs Three Fractions

NCT06743789
View directory record Official record
Conditions
Ventricular Tachycardia
Interventions
Radiation Therapy
Radiation
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
18 Years to 90 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2030
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jan 25, 2026 · Synced Sep 4, 2026, 7:33 PM EDT
Completed No phase listed Observational

Single Ventricle Outcome

NCT00308217
View directory record Official record
Conditions
Heart Disease, Congenital, Single Ventricle, Hypoplastic Left Heart Syndrome
Interventions
Not listed
Lead sponsor
Emory University
Other
Eligibility
Not listed
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Dec 11, 2013 · Synced Sep 4, 2026, 7:33 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Evaluation of Safety, Tolerability, Pharmacokinetics, Drug-Drug and Food Interactions of Single and Multiple Doses of S-648414 in Healthy Adults

NCT04147715
View directory record Official record
Conditions
Healthy Volunteer
Interventions
S-648414, Placebo, Midazolam, Dolutegravir
Drug
Lead sponsor
Shionogi
Industry
Eligibility
18 Years to 55 Years
Enrollment
98 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2020
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Oct 31, 2021 · Synced Sep 4, 2026, 7:33 PM EDT
Terminated Phase 2Phase 3 Interventional Results available

Colchicine in Postoperative Fontan Patients

NCT03575572
View directory record Official record
Conditions
Single-ventricle, Heart Diseases
Interventions
Colchicine
Drug
Lead sponsor
University of Michigan
Other
Eligibility
20 Months to 5 Years
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated May 8, 2022 · Synced Sep 4, 2026, 7:33 PM EDT
Completed No phase listed Observational

Detection of Heart Conditions With Single Lead ECG Using Artificial Intelligence

NCT04400435
View directory record Official record
Conditions
Left Ventricular Dysfunction
Interventions
Use of Eko DUO electronic stethoscope
Device
Lead sponsor
Eko Devices, Inc.
Industry
Eligibility
18 Years and older
Enrollment
1,258 participants
Timeline
2020 – 2022
U.S. locations
3
States / cities
Los Alamitos, California • Washington D.C., District of Columbia • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Dec 8, 2022 · Synced Sep 4, 2026, 7:33 PM EDT
Completed No phase listed Observational

Fontan Imaging Biomarkers (FIB) Study

NCT03119090
View directory record Official record
Conditions
Single-ventricle, Congenital Heart Disease
Interventions
Not listed
Lead sponsor
Boston Children's Hospital
Other
Eligibility
3 Years and older
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2021
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Nov 4, 2021 · Synced Sep 4, 2026, 7:33 PM EDT
Suspended No phase listed Observational

Augmented Ultrasound-Facilitated, Catheter-Directed Fibrinolysis for PE

NCT06310018
View directory record Official record
Conditions
Pulmonary Embolism, Right Ventricular Dysfunction, Right Ventricular Failure
Interventions
Ultrasound-facilitated, catheter-directed lower-dose fibrinolysis, Tissue Plasminogen Activator
Device · Drug
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2027 – 2028
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jan 20, 2026 · Synced Sep 4, 2026, 7:33 PM EDT
Recruiting Phase 1 Interventional

IMProving DRug Dosing and Outcomes for Single VEntricle Patients With Fontan Associated Liver Disease

NCT06324396
View directory record Official record
Conditions
Fontan Circulation
Interventions
Sildenafil 10mg oral tablet (participants <20kg), or 20mg oral tablet (participants ≥20kg), Pravastatin 20 mg oral tablet (ages <13 years), or 40 mg oral tablet (≥14 years)
Drug
Lead sponsor
Children's Mercy Hospital Kansas City
Other
Eligibility
8 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
Kansas City, Missouri
Source: ClinicalTrials.gov public record
Updated Jan 1, 2026 · Synced Sep 4, 2026, 7:33 PM EDT
Completed Not applicable Interventional Results available

Training in Exercise Activities and Motion for Growth

NCT01917084
View directory record Official record
Conditions
Single Ventricle Physiology
Interventions
Passive range of motion (ROM) exercise
Other
Lead sponsor
Carelon Research
Other
Eligibility
1 Day to 30 Days
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
3
States / cities
Philadelphia, Pennsylvania • Houston, Texas • Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Feb 19, 2025 · Synced Sep 4, 2026, 7:33 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Frailty in Children With Cardiac Disease

NCT02999438
View directory record Official record
Conditions
Pulmonary Hypertension, Heart Failure, Single Ventricle
Interventions
Actigraph to check activity levels at home
Device
Lead sponsor
Children's Mercy Hospital Kansas City
Other
Eligibility
8 Years to 18 Years
Enrollment
56 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2022
U.S. locations
1
States / cities
Kansas City, Missouri
Source: ClinicalTrials.gov public record
Updated Jul 13, 2023 · Synced Sep 4, 2026, 7:33 PM EDT
Completed Phase 1 Interventional

A Phase I Study to Assess the Electrophysiologic Effects of BMS-394136 on the Atrium and Ventricle in Patients With Dual-Chamber Pacemakers or Defibrillators

NCT00162448
View directory record Official record
Conditions
Heart Diseases
Interventions
BMS-394136, Placebo
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years to 80 Years
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2005
U.S. locations
3
States / cities
Salisbury, Maryland • Ann Arbor, Michigan • Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Aug 19, 2008 · Synced Sep 4, 2026, 7:33 PM EDT
Completed No phase listed Observational

Genetic Determinants of Congenital Heart Disease Outcomes

NCT01656941
View directory record Official record
Conditions
Congenital Heart Disease, Hypoplastic Left Heart Syndrome, Hypoplastic Right Heart Syndrome, d-Transposition of the Great Arteries
Interventions
Not listed
Lead sponsor
University of Michigan
Other
Eligibility
Up to 30 Days
Enrollment
250 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2017
U.S. locations
4
States / cities
Atlanta, Georgia • Ann Arbor, Michigan • Charleston, South Carolina + 1 more
Source: ClinicalTrials.gov public record
Updated Aug 9, 2021 · Synced Sep 4, 2026, 7:33 PM EDT
Recruiting Not applicable Interventional

Impact of Early Fortini Initiation on Growth and Interstage Outcomes in Infants With Single Ventricle Physiology

NCT07087782
View directory record Official record
Conditions
Single-ventricle
Interventions
Fortini formula, Standard Nutritional Care
Other
Lead sponsor
Driscoll Children's Hospital
Other
Eligibility
0 Months to 6 Months
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
1
States / cities
Corpus Christi, Texas
Source: ClinicalTrials.gov public record
Updated May 12, 2026 · Synced Sep 4, 2026, 7:33 PM EDT
Completed Phase 4 Interventional Results available

The Effects of Ambrisentan on Exercise Capacity in Fontan Patients

NCT01971580
View directory record Official record
Conditions
Single Ventricle Fontan Palliation
Interventions
Ambrisentan
Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years to 50 Years
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated May 6, 2018 · Synced Sep 4, 2026, 7:33 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Randomized, Single-Dose, Comparative, Positive and Placebo Controlled, Four-Way, Four Period, Cross-Over Study to Evaluate the Effect of DIC075V on QTc Intervals in Healthy Subjects

NCT01812538
View directory record Official record
Conditions
Ventricular Repolarization
Interventions
DIC075V
Drug
Lead sponsor
Hospira, now a wholly owned subsidiary of Pfizer
Industry
Eligibility
18 Years to 50 Years
Enrollment
70 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009
U.S. locations
1
States / cities
Fargo, North Dakota
Source: ClinicalTrials.gov public record
Updated Jul 23, 2015 · Synced Sep 4, 2026, 7:33 PM EDT
Recruiting No phase listed Observational

Transcatheter Fontan Stenting: Impact on Hepatic Stiffness and Exercise Capacity

NCT07073612
View directory record Official record
Conditions
Single-ventricle, Stenosis
Interventions
Cardiopulmonary Exercise Testing (CPET), Shear Wave Elastography Scan
Diagnostic Test
Lead sponsor
Children's Hospital Los Angeles
Other
Eligibility
12 Years to 21 Years
Enrollment
20 participants
Timeline
2025 – 2027
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Jul 17, 2025 · Synced Sep 4, 2026, 7:33 PM EDT
Completed Phase 1 Interventional

A Pilot Study Investigating the Clinical Use of Tissue Engineered Vascular Grafts in Congenital Heart Surgery

NCT01034007
View directory record Official record
Conditions
Single Ventricle Cardiac Anomaly
Interventions
Tissue Engineered Vascular Grafts
Combination Product
Lead sponsor
Christopher Breuer
Other
Eligibility
1 Year to 100 Years
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2018
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Mar 1, 2018 · Synced Sep 4, 2026, 7:33 PM EDT